第五章 結論與展望
5.3 未來展望
物，會增加罹患慢性腎臟病的共病，如：糖尿病、高血壓、高血脂、心臟病的勝算，
是否因藥物關係先導致糖尿病、高血壓、高血脂、心臟病之慢性腎臟病共病，之後 才導致慢性腎臟病，其生物機制有待更進一步實驗確認。
5.2 研究限制
健保資料庫含有大量病人就診資料，促使近幾年大量被發表探勘，以流行病學 統計方式找出疾病的關聯性，提供臨床醫生或是生物學家做進一步實驗之先備知 識。健保資料庫百萬人口歸人檔其資料非常寶貴，但是並未提供對於精神分裂症與 慢性腎臟病之研究定義，甚至於慢性腎臟病的共病資料如何取得與定義，皆未明確 指示，而本研究之研究設計與統計方法，皆是參考大量健保資料庫已發表文獻，或 是流行病學相關書籍其做法而加以調整修改，其健保資料庫並未有生化值、抽菸習 慣、飲酒習慣之病人生活型態之紀錄，這些限制或許將來可以用問卷或是臨床實驗 加以分析探討。
5.3 未來展望
本研究是第一個利用台灣健保資料庫百萬歸人檔，使用流行病學數據統計分 析方式，指出精神分裂症病患有較高的風險罹患慢性腎臟病，並與精神分裂症病患 服用抗精神病藥物無統計上顯著相關。本研究希望提供臨床醫生或生物學家為一 研究新發現，是否有其生物機制可依循，有待醫生或生物學家進一步探討。
54
參考文獻
1. Fusar-Poli, P. and P. Politi, Paul Eugen Bleuler and the birth of Schizophrenia (1908). Am J Psychiatry, 2008. 165(11): p. 1407.
2. Shaw, S.H., et al., A genome-wide search for Schizophrenia susceptibility genes.
Am J Med Genet, 1998. 81(5): p. 364-76.
3. Schmidt, M.H., Diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders IV. Zeitschrift Fur Kinder-Und Jugendpsychiatrie Und Psychotherapie, 1999. 27(1): p. 77-77.
4. Higaki, T., et al., Quantification and cluster analysis of actin cytoskeletal structures in plant cells: role of actin bundling in stomatal movement during diurnal cycles in Arabidopsis guard cells. Plant J, 2010. 61(1): p. 156-65.
5. Kelly, D.L., Treatment considerations in women with schizophrenia. J Womens Health (Larchmt), 2006. 15(10): p. 1132-40.
6. Russell, A.T., The clinical presentation of childhood-onset schizophrenia.
Schizophr Bull, 1994. 20(4): p. 631-46.
7. Roberson, C., Schizophrenia. Ala Nurse, 2009. 36(2): p. 6-8.
8. Sernyak, M.J., et al., Association of diabetes mellitus with use of atypical neuroleptics in the treatment of Schizophrenia. American Journal of Psychiatry, 2002. 159(4): p. 561-566.
9. Gaebel, W., et al., Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry, 2005. 187: p. 248-55.
10. Shirzadi, A.A. and S.N. Ghaemi, Side effects of atypical antipsychotics:
extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry, 2006. 14(3): p. 152-64.
11. Stahl, S.M., Polypharmacy in schizophrenia: A fuzzy concept - Dr. Stahl replies.
Journal of Clinical Psychiatry, 2003. 64(9): p. 1132-1133.
12. Tandon, R. and M.D. Jibson, Extrapyramidal side effects of antipsychotic
treatment: scope of problem and impact on outcome. Ann Clin Psychiatry, 2002.
14(2): p. 123-9.
13. Jesic, M.P., et al., Extrapyramidal syndromes caused by antipsychotics. Med Pregl, 2012. 65(11-12): p. 521-6.
14. Haddad, P.M., et al., Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J
Psychopharmacol, 2012. 26(5 Suppl): p. 15-26.
15. Nadkarni, A., et al., Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy. Clinicoecon Outcomes
55
Res, 2013. 5: p. 49-57.
16. Kapur, S. and D. Mamo, Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry, 2003.
27(7): p. 1081-90.
17. Tamminga, C.A., R.W. Buchanan, and J.M. Gold, The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol, 1998. 13 Suppl 3: p. S21-6.
18. Tandon, R. and U. Halbreich, The second-generation 'atypical' antipsychotics:
similar improved efficacy but different neuroendocrine side effects.
Psychoneuroendocrinology, 2003. 28 Suppl 1: p. 1-7.
19. Ucok, A. and W. Gaebel, Side effects of atypical antipsychotics: a brief overview.
World Psychiatry, 2008. 7(1): p. 58-62.
20. Meyer, J.M. and C.E. Koro, The effects of antipsychotic therapy on serum lipids:
a comprehensive review. Schizophr Res, 2004. 70(1): p. 1-17.
21. Nasrallah, H.A. and J.W. Newcomer, Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol, 2004. 24(5 Suppl 1): p. S7-14.
22. Wu, R.R., et al., Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Psychopharmacology (Berl), 2006. 186(4): p. 572-8.
23. Meyer, J., C.E. Koro, and G.J. L'Italien, The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry, 2005. 17(3): p. 173-80.
24. Henderson, D.C., Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs, 2002. 16(2): p. 77-89.
25. Cohen, D., Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry, 2004. 37(1): p. 1-11.
26. Newcomer, J.W., Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 2005. 19 Suppl 1: p. 1-93.
27. Schneider, L.S., K.S. Dagerman, and P. Insel, Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 2005. 294(15): p. 1934-43.
28. Cooper, E., Online drug information resources: free alternatives. Med Ref Serv Q, 2008. 27(1): p. 97-103.
29. Johnson, C.A., et al., Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors.
Am Fam Physician, 2004. 70(5): p. 869-76.
30. National Kidney, F., K/DOQI clinical practice guidelines for chronic kidney
56
disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002.
39(2 Suppl 1): p. S1-266.
31. Klatsky, A.L., et al., Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med, 1977. 296(21): p. 1194-200.
32. MacMahon, S.W. and R.N. Norton, Alcohol and hypertension: implications for prevention and treatment. Ann Intern Med, 1986. 105(1): p. 124-6.
33. Marmot, M. and E. Brunner, Alcohol and cardiovascular disease: the status of the U shaped curve. BMJ, 1991. 303(6802): p. 565-8.
34. Thomas, N. and R. Bryar, An evaluation of a self-management package for people with diabetes at risk of chronic kidney disease. Prim Health Care Res Dev, 2013: p. 1-11.
35. Sakraida, T.J. and M.V. Robinson, Mental health and relational self-management experiences of patients with type 2 diabetes and stage 3 chronic kidney disease.
Issues Ment Health Nurs, 2012. 33(11): p. 786-96.
36. Assogba, G.F., et al., Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and 2007). Diabetes Metab, 2012. 38(6): p. 558-66.
37. Jurkovitz, C.T., et al., Association between lack of health insurance and risk of death and ESRD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis, 2013. 61(4 Suppl 2): p. S24-32.
38. Mahfoud, F., D. Linz, and M. Bohm, [Heart and kidneys. Renal denervation as therapy for hypertension]. Herz, 2013. 38(1): p. 67-75; quiz 76-8.
39. Yano, Y. and G.L. Bakris, Recognition and management of masked hypertension:
A review and novel approach. J Am Soc Hypertens, 2013. 7(3): p. 244-52.
40. Chang, T.I., et al., Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis, 2013. 61(4 Suppl 2): p. S4-11.
41. Thomas, R., A. Kanso, and J.R. Sedor, Chronic kidney disease and its complications. Prim Care, 2008. 35(2): p. 329-44, vii.
42. Snively, C.S. and C. Gutierrez, Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician, 2004. 70(10): p. 1921-8.
43. Flores, J.C., et al., [Clinical guidelines on identification, management and
complications of chronic kidney disease]. Rev Med Chil, 2009. 137(1): p. 137-77.
44. Sera, N., et al., The association between chronic kidney disease and
cardiovascular disease risk factors in atomic bomb survivors. Radiat Res, 2013.
179(1): p. 46-52.
45. McClellan, W.M., et al., Chronic kidney disease is often unrecognized among
57
patients with coronary heart disease: The REGARDS Cohort Study. Am J Nephrol, 2009. 29(1): p. 10-7.
46. Polonsky, T.S. and G.L. Bakris, Chronic kidney disease: a coronary heart disease equivalent? Lancet, 2012. 380(9844): p. 783-5.
47. Athyros, V.G., et al., Stage of chronic kidney disease and severity of coronary heart disease manifestation. Expert Opin Pharmacother, 2012. 13(4): p. 457-60.
48. Ramkumar, N., et al., Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr, 2004. 14(4): p. 201-7.
49. Hall, J.E., et al., Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther, 2004. 11(1): p. 41-54.
50. Stengel, B., et al., Lifestyle factors, obesity and the risk of chronic kidney disease.
Epidemiology, 2003. 14(4): p. 479-87.
51. Kramer, H., Obesity and chronic kidney disease. Contrib NepORol, 2006. 151: p.
1-18.
52. Gooch, K., et al., NSAID use and progression of chronic kidney disease. Am J Med, 2007. 120(3): p. 280 e1-7.
53. Steele, M.R., V. Belostotsky, and K.K. Lau, The dangers of substance abuse in adolescents with chronic kidney disease: a review of the literature. CANNT J, 2012. 22(1): p. 15-22; quiz 23-4.
54. Di Biagio, A., et al., Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study. Clin Nephrol, 2011. 75(6): p. 518-23.
55. Vupputuri, S., et al., History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol, 2004. 14(3): p. 222-8.
56. Hsu, Y.H., et al., Association of betel nut chewing with chronic kidney disease: a retrospective 7-year study in Taiwan. Nephrology (Carlton), 2011. 16(8): p. 751-7.
57. Freedman, R., Schizophrenia. N Engl J Med, 2003. 349(18): p. 1738-49.
58. Chien, I.C., et al., Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996-2001. Psychiatry Clin Neurosci, 2004.
58(6): p. 611-8.
59. Tsai, K.Y., et al., The incidence and relative risk of stroke in patients with
schizophrenia: a five-year follow-up study. Schizophr Res, 2012. 138(1): p. 41-7.
60. Bresee, L.C., et al., Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. Eur Psychiatry, 2011. 26(5): p. 327-32.
61. Kelly, D.L., et al., Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry, 2010. 71(3): p. 304-11.
58
62. Dobrin, I., et al., [Cardiovascular risk of haloperidol vs. atypical anti-psychotic drugs in schizophrenia treatment]. Rev Med Chir Soc Med Nat Iasi, 2010.
114(3): p. 658-61.
63. Ferreira, L., et al., A case-control study of cardiovascular risk factors and cardiovascular risk among patients with schizophrenia in a country in the low cardiovascular risk region of Europe. Rev Port Cardiol, 2010. 29(10): p. 1481-93.
64. Bobes, J., et al., Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res, 2010. 119(1-3): p. 101-9.
65. Bresee, L.C., et al., Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. SchizopOR Res, 2010.
117(1): p. 75-82.
66. Lin, H.C., et al., Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res, 2010. 116(1): p. 55-60.
67. Tormoehlen, K. and M. Lessick, Schizophrenia in women: implications for pregnancy and postpartum. Nurs Womens Health, 2010. 14(6): p. 482-94; quiz 495.
68. Chien, I.C., et al., Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res, 2009. 111(1-3): p. 17-22.
69. Tabata, H., et al., Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai, 1987. 70 Suppl 2: p. 90-3.
70. Mukherjee, S., et al., Diabetes mellitus in schizophrenic patients. Compr Psychiatry, 1996. 37(1): p. 68-73.
71. Dixon, L., et al., Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull, 2000. 26(4): p. 903-12.
72. Rouillon, F. and F. Sorbara, Schizophrenia and diabetes: epidemiological data.
Eur Psychiatry, 2005. 20 Suppl 4: p. S345-8.
73. Cohen, D., et al., Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur
Neuropsychopharmacol, 2006. 16(3): p. 187-94.
74. Gianfrancesco, F., et al., Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol, 2003. 23(4): p. 328-35.
75. Hung, C.F., C.K. Wu, and P.Y. Lin, Diabetes mellitus in patients with schizophrenia in Taiwan. Prog Neuropsychopharmacol Biol Psychiatry, 2005. 29(4): p. 523-7.
76. Ko, G.T., et al., A low socio-economic status is an additional risk factor for glucose intolerance in high risk Hong Kong Chinese. Eur J Epidemiol, 2001.
17(3): p. 289-95.
59
77. Chien, I.C., et al., Prevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv, 2004. 55(6): p. 691-7.
78. Subramaniam, M., S.A. Chong, and E. Pek, Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry, 2003. 48(5):
p. 345-7.
79. Philippe, A., G. Vaiva, and F. Casadebaig, Data on diabetes from the French cohort study in schizophrenia. Eur Psychiatry, 2005. 20 Suppl 4: p. S340-4.
80. Sernyak, M.J., et al., Association of diabetes mellitus with use of atypical
neuroleptics in the treatment of schizophrenia. Am J Psychiatry, 2002. 159(4): p.
561-6.
81. Lindenmayer, J.P., et al., Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry, 2003. 160(2): p. 290-6.
82. Baptista, T., Mechanisms of weight gain induced by antipsychotic drugs. J Clin Psychiatry, 2002. 63(3): p. 245-6.
83. Kroeze, W.K., et al., H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology, 2003. 28(3): p. 519-26.
84. Casey, D.E. and S.H. Zorn, The pharmacology of weight gain with antipsychotics.
J Clin Psychiatry, 2001. 62 Suppl 7: p. 4-10.
85. Brown, S., et al., The unhealthy lifestyle of people with schizophrenia. Psychol Med, 1999. 29(3): p. 697-701.
86. Curkendall, S.M., et al., Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry, 2004. 65(5): p. 715-20.
87. Bih, S.H., et al., The treated prevalence and incidence of bipolar disorder among national health insurance enrollees in Taiwan, 1996-2003. Soc Psychiatry
Psychiatr Epidemiol, 2008. 43(11): p. 860-5.
88. Sacchetti, E., C. Turrina, and P. Valsecchi, Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf, 2010.
33(4): p. 273-88.
89. Newman, S.C. and R.C. Bland, Mortality in a cohort of patients with
schizophrenia: a record linkage study. Can J Psychiatry, 1991. 36(4): p. 239-45.
90. Saha, S., D. Chant, and J. McGrath, A systematic review of mortality in
schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry, 2007. 64(10): p. 1123-31.
91. Ruetsch, O., et al., [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].
Encephale, 2005. 31(4 Pt 1): p. 507-16.
60
92. McCreadie, R.G. and G. Scottish Schizophrenia Lifestyle, Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry, 2003. 183: p. 534-9.
93. Leys, D., et al., Stroke prevention: management of modifiable vascular risk factors. J Neurol, 2002. 249(5): p. 507-17.
94. Leucht, S., et al., Physical illness and schizophrenia: a review of the literature.
Acta Psychiatr Scand, 2007. 116(5): p. 317-33.
95. Homel, P., D. Casey, and D.B. Allison, Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res, 2002. 55(3): p. 277-84.
96. Sweileh, W.M., et al., Diabetes mellitus in patients with schizophrenia in West-Bank, Palestine. Diabetes Res Clin Pract, 2013. 99(3): p. 351-7.
97. Takayanagi, Y., et al., Diabetes is associated with lower global cognitive function in schizophrenia. Schizophrenia Research, 2012. 142(1-3): p. 183-187.
98. Alkelai, A., et al., Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS One, 2012.
7(1): p. e29228.
99. Erickson, S.C., et al., New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. J Am Geriatr Soc, 2012. 60(3): p. 474-9.
100. Schoepf, D., et al., Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur Psychiatry, 2012. 27(1): p. 33-42.
101. Kusumi, I., et al., Screening for diabetes using monitoring guidance in
schizophrenia patients treated with second-generation antipsychotics: A 1-year follow-up study. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2011. 35(8): p. 1922-1926.
102. Liao, C.H., et al., Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: A population-based study. Schizophrenia Research, 2011.
126(1-3): p. 110-116.
103. Hsu, J.H., et al., Incidence of diabetes in patients with schizophrenia: a population-based study. Can J Psychiatry, 2011. 56(1): p. 19-26.
104. Subashini, R., et al., Prevalence of diabetes, obesity, and metabolic syndrome in subjects with and without schizophrenia (CURES-104). Journal of Postgraduate Medicine, 2011. 57(4): p. 272-277.
105. Becker, T. and J. Hux, Risk of Acute Complications of Diabetes Among People With Schizophrenia in Ontario, Canada. Diabetes Care, 2011. 34(2): p. 398-402.
61
106. Tang, C.Y., et al., The effects of hypertension and body mass index on diffusion tensor imaging in schizophrenia. Schizophr Res, 2011. 130(1-3): p. 94-100.
107. Saddichha, S. and S. Akhtar, Prehypertension, Hypertension and Cardiometabolic Changes Associated with Antipsychotic Use in Schizophrenia. Basic & Clinical Pharmacology & Toxicology, 2011. 109: p. 33-33.
108. Lev-Ran, S., Y. Le Strat, and B. Le Foll, Impact of hypertension and body mass index on quality of life in schizophrenia. Am J Psychiatry, 2011. 168(5): p. 552-3.
109. Friedman, J.I., et al., The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry, 2010. 167(10): p. 1232-9.
110. Saddichha, S., N. Manjunatha, and S. Akhtar, Obesity, Diabetes and
Hypertension Associated with Antipsychotic Use in Drug Naive Schizophrenia.
Australian and New Zealand Journal of Psychiatry, 2010. 44: p. A12-A13.
111. Piette, J.D., et al., Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatric Services, 2007. 58(2): p. 207-212.
112. Johannessen, L., et al., Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord, 2006. 95(1-3): p. 13-7.
113. Nasrallah, H.A., et al., Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 2006. 86(1-3): p. 15-22.
114. Lund, B.C., et al., Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension - A claims-based approach. Archives of General Psychiatry, 2001. 58(12): p. 1172-1176.
115. Hsu, J.H., et al., Hyperlipidemia in patients with schizophrenia: a national population-based study. Gen Hosp Psychiatry, 2012. 34(4): p. 360-7.
116. Erickson, S.C., et al., New-Onset Treatment-Dependent Diabetes Mellitus and Hyperlipidemia Associated with Atypical Antipsychotic Use in Older Adults without Schizophrenia or Bipolar Disorder. Journal of the American Geriatrics Society, 2012. 60(3): p. 474-479.
117. Darba, J., et al., A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs. Annals of Clinical Psychiatry, 2013.
25(1): p. 17-26.
118. Birkhofer, A., et al., The deceleration capacity - a new measure of heart rate variability evaluated in patients with schizophrenia and antipsychotic treatment. European Psychiatry, 2013. 28(2): p. 81-86.
119. Kim, J.H., et al., Effects of Clozapine on Heart Rate Dynamics and Their
62
Relationship With Therapeutic Response in Treatment-Resistant Schizophrenia.
Journal of Clinical Psychopharmacology, 2013. 33(1): p. 69-73.
120. Lee, K., et al., Heart Rate Variability and Metabolic Syndrome in Hospitalized Patients with Schizophrenia. Journal of Korean Academy of Nursing, 2011.
41(6): p. 788-794.
121. Arango, C., et al., Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study. European
Neuropsychopharmacology, 2011. 21(12): p. 867-875.
122. Rachow, T., et al., Nonlinear relationship between electrodermal activity and heart rate variability in patients with acute schizophrenia. Psychophysiology, 2011. 48(10): p. 1323-1332.
123. Kim, J.H., J.H. Ann, and J. Lee, Relationship between heart rate variability and the severity of psychotic symptoms in schizophrenia. Acta Neuropsychiatrica, 2011. 23(4): p. 161-166.
124. Laursen, T.M. and M. Nordentoft, Heart disease treatment and mortality in schizophrenia and bipolar disorder - Changes in the danish population between 1994 and 2006. Journal of Psychiatric Research, 2011. 45(1): p. 29-35.
125. Henry, B.L., et al., Heart rate variability in bipolar mania and schizophrenia. J Psychiatr Res, 2010. 44(3): p. 168-76.
126. Barnett, A.H., et al., UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Eur Arch Psychiatry Clin Neurosci, 2009. 259(4): p. 239-47.
127. Nurjono, M. and J. Lee, Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in Singapore. Early Interv Psychiatry, 2013. 7(2): p. 205-9.
128. Yu, W., et al., CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol, 2013. 33(2): p. 186-92.
129. Suzuki, Y., et al., Low prevalence of metabolic syndrome and its prediction in Japanese inpatients with schizophrenia. Hum Psychopharmacol, 2013. 28(2): p.
188-91.
130. Mitchell, A.J., et al., Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients. Schizophrenia Bulletin, 2013.
39(2): p. 295-305.
131. Lee, N.Y., et al., The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with
schizophrenia. International Clinical Psychopharmacology, 2013. 28(2): p. 71-79.
63
132. Grover, S., et al., Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry Research, 2012. 200(2-3): p. 1035-1037.
133. Sweileh, W.M., et al., Prevalence of metabolic syndrome among patients with Schizophrenia in Palestine. Bmc Psychiatry, 2012. 12.
134. Na, K.S., et al., Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2012. 39(2): p. 295-300.
135. Said, M.A., et al., Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia. Singapore Medical Journal, 2012. 53(12): p. 801-807.
136. Lindenmayer, J.P., et al., Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophrenia Research, 2012. 142(1-3): p. 171-176.
137. Zhang, L., et al., Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet, 2012. 379(9818): p. 815-22.
138. Baigent, C., et al., The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011. 377(9784): p.
2181-92.
139. James, M.T., et al., Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet, 2010. 376(9758): p.
2096-103.
140. Chronic Kidney Disease Prognosis, C., et al., Association of estimated glomerular
140. Chronic Kidney Disease Prognosis, C., et al., Association of estimated glomerular